Raynaud’s phenomenon

Raynaud M: Local Asphyxia and Symmetrical Gangrene of the Extremities 1862. New Researches on the Nature and Treatment of Local Asphyxia of the Extremities 1874. Translated by Barlow T. London: New Sydenham Society; 1888.

Wigley FM: Raynaud’s phenomenon. N Eng J Med 2002, 347:1001–1008.

Herrick AL: Pathogenesis of Raynaud’s phenomenon. Rheumatology 2005, 44:587–596.

Fishman AP: Pulmonary hypertension-beyond vasodilator therapy. N Eng J Med 1998, 338:321–322.

Chrysant SG: Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998, 135:S21–S30.

Kirchengast M, Münter K: Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999, 221:312–325.

Campbell PM, LeRoy EC: Pathogenesis of systemic sclerosis: a vascular hypothesis. Sem Arthritis Rheum 1975, 4:351–368.

Rodnan GP, Myerowitz RL, Justh GO: Morphological changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine 1980, 59:393–408.

Harrison BJ, Silman AJ, Hider SL, Herrick AL: Cigarette smoking: a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 2002, 46:3312–3316.

Raynaud’s Treatment Study Investigators: Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000, 160:1101–1108.

Kahaleh MB, Osborn I, LeRoy EC: Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Int Med 1982, 96:610–613.

Merkel PA, Herlyn K, Martin RW, et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002, 46:2410–2420.

Korn JH, Mayes M, Matucci Cerinic M, et al.: for the RAPIDS-1 Study Group: Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985–3993.

Gliddon AE, Dor’e CJ, Black CM, et al.: Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a randomised controlled trial of the ACE-inhibitor quinapril. Arthritis Rheum 2007, 56:3837–3846.

Malamet R, Wise RA, Ettinger WH, Wigley FM: Nifedipine in the treatment of Raynaud’s phenomenon. Evidence for inhibition of platelet activation. Am J Med 1985, 78:602–608.

Allanore Y, Borderie D, Lemarechal H, et al.: Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004, 116:595–600.

Thompson AE, Pope JE: Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology 2005, 44:145–150.

Thompson AE, Shea B, Welch V, et al.: Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 2001, 44:1841–1847.

Dziadzio M, Denton CP, Smith R, et al.: Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646–2655.

Pope J, Fenlon D, Thompson A, et al.: Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000956.

Pope J, Fenlon D, Thompson A, et al.: Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000953.

Wigley FM, Korn JH, Csuka ME, et al.: Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multi-center, placebo-controlled, double-blind study. Arthritis Rheum 1998, 41:670–677.

Vayssairat M: Preventative effect of an oral prostacyclin analog, beroprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999, 26:2173–2178.

Wigley FM, Wise RA, Seibold JR, et al.: Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, doubleblind study. Ann Intern Med 1994, 120:199–206.

Seibold JR, Matucci-Cerinic M, Denton CP, et al.: Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis [abstract]. Ann Rheum Dis 2006, 65(Suppl II):90.

Pope J, Fenlon D, Thompson A, et al.: Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000954.

Coleiro B, Marshall SE, Denton CP, et al.: Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001, 40:1038–1043.

Yee AM, Hotchkiss RN, Paget SA: Adventitial stripping: adigit saving procedure in refractory Raynaud’s phenomenon. J Rheumatol 1998, 25:269–276.

McCall TE, Petersen DP, Wong LB: The use of digital artery sympathectomy as a salvage procedure for severe ischemia of Raynaud’s disease and phenomenon. J Hand Surg [Am] 1999, 24:173–177.

Tomaino MM, Goitz RJ, Medsger TA: Surgery for ischemic pain and Raynaud’s phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery 2001, 21:75–79.

Kotsis SV, Chung KC: A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003, 30:1788–1792.

Taylor MH, McFadden JA, Bolster MB, Silver RM: Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 2002, 29:102–106.

Klyscz T, Junger M, Meyer H, Rassner G: Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks. Vasa 1998, 27:39–42.

Veale DJ, Collidge TA, Belch JJF: Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995, 54:853–855.

Teh LS, Manning J, Moore T, et al.: Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 1995, 34:636–641.

Khan F, Greig IR, Newton DJ, et al.: Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet 1997, 350:410–411.

Tucker AT, Pearson RM, Cooke ED, Benjamin N: Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud’s syndrome: a randomised trial. Lancet 1999, 354:1670–1675.

Anderson ME, Moore TL, Hollis S, et al.: Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology 2002, 41:324–328.

Chung L, Baron M, Collier D, et al.: A multi-center placebo-controlled “in-life” study of MQX-503 in patients with Raynaud’s phenomenon [abstract]. Arthritis Rheum 2007, 56(Suppl):S824.

Kumana CR, Cheung GTY, Lau CS: Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 2004, 63:1522–1524.

Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980–2985.

Gore J, Silver R: Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005, 64:1387.

Caglayan E, Huntegeburth M, Karasch T, et al.: Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Int Med 2006, 166:231–233.

Rajagopalan S, Pfenninger D, Somers E, et al.: Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol 2003, 92:1310–1315.

Herrick AL, Matucci Cerinic M: The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001, 19:4–8.

Denton CP, Bunce TD, Dorado MB, et al.: Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology 1999, 38:309–315.

Herrick AL, Hollis S, Schofield D, et al.: A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000, 18:349–356.

Beckett VL, Conn DL, Fuster V, et al.: Trial of platelet-inhibiting drug in scleroderma. Arthritis Rheum 1984, 27:1137–1143.

Chotani MA, Flavahan S, Mitra S, et al.: Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000, 278:H1075–H1083.

Wise RA, Wigley FM, White B, et al.: Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. A single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004, 50:3994–4001.